Lidocaine and Dexmedetomidine Infusion and Their Combination on Perioperative Pain in Patients Undergoing Video-Assisted Thoracoscopic Surgery

Last updated: February 20, 2025
Sponsor: Ain Shams University
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Dexmedetomidine

Lidocaine

Lidocaine and Dexmedetomidine

Clinical Study ID

NCT06837519
FMASU R22/2025
  • Ages > 18
  • All Genders

Study Summary

This study aims to compare lidocaine and dexmedetomidine infusion and their combination on perioperative pain in patients undergoing video-assisted thoracoscopic surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years old.

  • Both sexes.

  • American Society of Anesthesiologists (ASA) physical status of I, II.

  • Patients undergoing video-assisted thoracoscopic surgery (VATS) under generalanesthesia.

Exclusion

Exclusion Criteria:

  • Hypersensitivity to any of the used drugs.

  • Coagulation disorder.

  • Body mass index >35 kg/m2.

  • History of chronic pain requiring daily opioids/steroids/clonidine/other α2agonist/analgesics or any drugs acting on the central nervous system during theprevious 2 weeks, and drug/alcohol abuse.

  • Contraindication to the use of local anesthetics.

  • Cardiovascular disease.

  • Severe respiratory, renal or hepatic impairment.

  • Insulin-dependent diabetes mellitus.

  • Central nervous system or psychiatric disease.

Study Design

Total Participants: 75
Treatment Group(s): 3
Primary Treatment: Dexmedetomidine
Phase:
Study Start date:
February 20, 2025
Estimated Completion Date:
August 01, 2025

Study Description

Video-assisted thoracoscopic surgery (VATS) is a minimally invasive procedure allowing the reduction of surgical stress. However, postoperative pain management is crucial for patients undergoing VATS, as inadequate pain control can lead to complications (such as lung atelectasis), prolonged recovery, and decreased patient satisfaction.

Dexmedetomidine has shown positive effects on postoperative pain intensity, opioid consumption and other recovery parameters, such as postoperative nausea and vomiting (PONV), and speed of recovery.

Lidocaine has exhibited an excellent safety profile when administered as a low-dose infusion for cancer or non-cancer chronic pain.

Connect with a study center

  • Ain Shams University

    Cairo, 11591
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.